(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 December 2018 (06.12.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/223101 A1

(51) International Patent Classification:
A61K 35/17 (2015.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2018/035755

(22) International Filing Date:
01 June 2018 (01.06.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/514,774	02 June 2017 (02.06.2017)	US
62/515,530	05 June 2017 (05.06.2017)	US
62/521,366	16 June 2017 (16.06.2017)	US
62/527,000	29 June 2017 (29.06.2017)	US
62/549,938	24 August 2017 (24.08.2017)	US
62/580,425	01 November 2017 (01.11.2017)	US
62/593,871	01 December 2017 (01.12.2017)	US
62/596,764	08 December 2017 (08.12.2017)	US
62/614,957	08 January 2018 (08.01.2018)	US

(71) Applicant: **JUNO THERAPEUTICS, INC.** [US/US]; 400 Dexter Ave. N., Suite 1200, Seattle, WA 98109 (US).


(72) Inventor: **ALBERTSON, Tina**; 400 Dexter Ave. N., Suite 1200, Seattle, WA 98109 (US).

(74) Agent: **AHN, Sejin** et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY

FIG. 31A



(57) Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

[Continued on next page]

WO 2018/223101 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*